Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Safety and Preliminary Efficacy of YAP101 in Subjects With Ischemic Heart Failure and Reduced Ejection Fraction

NCT06831825 is registered in ClinicalTrials.gov with Medley Therapeutics as lead sponsor.

NCT NCT06831825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06831825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Safety and Preliminary Efficacy of YAP101 in Subjects With Ischemic Heart Failure and Reduced Ejection Fraction
Lead sponsor
Medley Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
April 23, 2025
Completion date
June 30, 2027
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with reduced ejection fraction